Eli Lilly’s Abemaciclib: Better Than Competition In Breast Cancer?
- Abemaciclib has shown good results in combination with aromatase inhibitors in HR+/HER- metastatic breast cancer.
- So has the competition.
- It is difficult to assess which drug, if any, will win out, except that Abemaciclib has a different safety profile from the competition.
By Dr Udaya K Maiya, Oncologist, MBBS, MD, DNB, DCCF-Paris
Eli Lilly (LLY) is developing Abemaciclib for a number of indications including in Hormone-Receptor-Positive (HR+), HER2-negative metastatic breast cancer. The corresponding MONARCH 2 trial is in phase 3, the latest clinical stage for Abemaciclib, and the company reported positive results from this trial at ASCO 2017.
The full post is available to investor members only. Subscribe here.